25389-23-5

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 107-07-3 2-chloro-ethanol 
• 540-51-2 2-bromoethanol 
• 29936-92-3 ethyl 4-(ethoxycarbonyl)phenoxyacetate 
• 30893-58-4 4-(ethoxycarbonyl)phenoxyacetic acid 

Downstream Products

• 1027062-64-1 4-(2-Methanesulfonyloxy-ethoxy)-benzoic acid ethyl ester 
• 1711-24-6 4-(2-hydroxyethoxy)benzoic acid 
• 56442-09-2 ethyl 4-(2-phenoxyethoxy)benzoate 
• 22219-63-2 4-(2-phenoxy ethoxy)benzoic acid 
• 102895-59-0 1-[2-(4-ethoxycarbonyl-phenoxy)-ethyl]-4-phenyl-piperidine-4-carboxylic acid ethyl ester 
• 41386-38-3 4-(2-Bromo-ethoxy)-benzoic acid ethyl ester 
• 40992-21-0 4-(2-chloro-ethoxy)-benzoic acid ethyl ester 
• 170799-52-7 diethyl N-<4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoyl>-L-glutamate 
• 170799-60-7 ethyl 4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoate 
• 149325-67-7 4-<2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethoxy>benzoic acid 
• 170799-65-2 ethyl 4-<2-(2-cyano-3-methoxy-2-cyclopentenyl)ethoxy>benzoate 
• 56703-36-7 4-(2-Iodoethoxy)-benzoic acid ethyl ester 

Relevant academic research and scientific papers

DIOXETANE COMPOUND, CATIONICALLY POLYMERIZABLE COMPOSITION, OPTICAL FILM AND LIQUID CRYSTAL DISPLAY UNIT

The present invention provides a novel dioxetane compound having a cationically polymerizable oxetane group, which compound is excellent in compatibility with a liquid crystalline compound and a non-liquid crystalline compound. The present invention also provides an optical film with excellent liquid crystal orientation retention properties and mechanical strength, produced by aligning a composition of the dioxetane compound and a cationically polymerizable compound in a liquid crystal orientation and fixing the liquid crystal orientation by polymerization, and a liquid crystal display device with the optical film.

Condensed pyrimidine derivative

A novel pyrimidine derivative having an excellent antitumor activity, which is represented by the following general formula (I) or a pharmacologically acceptable salt thereof: STR1 wherein R1 represents a hydroxyl or amino group; R2 represents a phenylene, pyridinediyl, thiendiyl, furandiyl or thiazoldiyl group, --CO2 R5 and --CO2 R6 may be the same or different from each other and each represents a carboxyl group or a carboxylic acid ester, the part STR2 A represents an oxygen atom, a group represented by the formula: STR3 (wherein R3 and R4 may be the same or different from each other and each represents a hydrogen or halogen atom or a hydrocarbon group which may be substituted, or alternatively R3 and R4 may be united to form an alkylidene group which may be substituted) or a group represented by the formula: STR4 (wherein R70 represents a hydrogen atom or a hydrocarbon group), and n is an integer of 1 to 3, provided that the compound in which R1 represents oxygen, and hydrogen is attached to nitrogen at 3-position is included in the above shown definition, a process for preparation the same, and an antitumor drug containing the same.

Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: Bridge modifications and heterocyclic benzoyl isosters of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate

Structural modifications of an extremely potent inhibitor of dihydrofolate reductase (DHFR) activity and tumor cell growth, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl ]benzoyl]-L-glutamic acid (1), have led to the synthesis of